BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]
233AS303
Phase 3 small_molecule active
Quick answer
BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo] for Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation is a Phase 3 program (small_molecule) at Biogen Idec Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Biogen Idec Ltd
- Indication
- Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active